glp-1 tachycardia Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology The Cardiovascular Biology of Glucagon-like

This strategy gets people focused on long-term solutions, instead of short-term fixes that dont hold

Membranes were sequentially incubated with primary antibodies (anti-GLP-1 [Santa Cruz, sc-80603, 1:1,000], anti-MPC2 [Proteintech, 20049-1-AP, 1:2000], anti-GAPDH [Cell Signaling, D4C6R-97166, 1:5,000]) overnight at 4 C, followed by HRP-conjugated secondary antibodies (Santa Cruz, sc-2354, 1:5,000) for 1 h at RT

Earlier studies using the 2.4 mg dose reported slightly lower results, with average weight loss around 17.5%, which shows how newer higher doses are narrowing the gap between Wegovy and Mounjaro

Whilst they offer metabolic benefits, they undergo fermentation in the colon, which can produce gas and bloating

Clinical Consensus Panel

10.1016/s2213-8587(18)30268-7 57 NielsenM